论文部分内容阅读
目的探讨联合化疗方案剂量强度对弥漫大B细胞淋巴瘤(DLBCL)患者预后的影响。方法初诊DLBCL患者64例,经化疗方案联合或不联合利妥昔单抗治疗,回顾性分析患者的年龄、国际预后指数(IPI)、化疗方案药物的平均相对剂量强度(ARDI)等因素对患者完全缓解(CR)率和1年生存率的影响。结果患者年龄>60岁、IPI评分3~5分患者的CR率和1年生存率均低于年龄≤60岁、IPI评分0~2分者(P<0.05)。患者化疗方案药物的ARDI≤90%的1年生存率亦低于ARDI>90%者(P<0.05)。年龄和化疗方案药物的ARDI是DLBCL患者疗效和预后的独立影响因素(P<0.05)。结论对于初诊的DLBCL患者,治疗过程中化疗方案药物的ARDI可影响患者预后。
Objective To investigate the effect of combination chemotherapy dose on the prognosis of patients with diffuse large B cell lymphoma (DLBCL). Methods Sixty-four patients with newly diagnosed DLBCL were treated with chemotherapy or without rituximab. The patients’ age, International Prognostic Index (IPI) and the mean relative dose intensity (ARDI) of the chemotherapy regimen were retrospectively analyzed. Complete remission (CR) rate and 1-year survival rate. Results The CR rate and 1-year survival rate of patients with age> 60 years and IPI score 3 ~ 5 were lower than those of patients ≤ 60 years old and IPI score 0 ~ 2 (P <0.05). The 1-year survival rate of ARDI ≤ 90% of patients receiving chemotherapy regimen was also lower than that of ARDI> 90% (P <0.05). ARDI of age and chemotherapy regimens was an independent predictor of outcome and outcome in patients with DLBCL (P <0.05). Conclusions ARDI for chemotherapy regimens during treatment may have an impact on the prognosis of patients with newly diagnosed DLBCL.